Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention
NCT ID: NCT01530490
Last Updated: 2012-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
80 participants
INTERVENTIONAL
2007-08-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome
NCT02461875
Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers
NCT01535859
Cabergoline and Coasting to Prevent OHSS
NCT01984320
Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
NCT07043322
Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome
NCT02134249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Slow infusion of 500 ml of 6% HES during follicular aspiration alone or combined with 0.5 mg cabergoline administration for 8 days, starting on the day of hCG administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hemoes
No interventions assigned to this group
Cabergoline
cabergoline
Cabergoline and Hydroxyethyl Starch
0.5mg
Hydroxyethyl Starch
0.5 mg cabergoline administration 8 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cabergoline and Hydroxyethyl Starch
0.5mg
Hydroxyethyl Starch
0.5 mg cabergoline administration 8 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital de Cruces
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roberto Matorras
Head of reproduction Unit
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roberto Matorras, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hospital Cruces
References
Explore related publications, articles, or registry entries linked to this study.
Matorras R, Andres M, Mendoza R, Prieto B, Pijoan JI, Exposito A. Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch. Eur J Obstet Gynecol Reprod Biol. 2013 Oct;170(2):439-43. doi: 10.1016/j.ejogrb.2013.07.010. Epub 2013 Aug 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIC0754
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.